Right about the drop, wrong about the dividend — Bayer, February 2024

On 19 February 2024, Bayer told the market it would pay "the legally required minimum" dividend — €0.11 per share, a cut of roughly 95% — and keep it there for three years. The reason wasn't a bad quarter; it was the balance sheet: tens of billions of net debt, high rates, a stretched free-cash-flow profile, and an open-ended Roundup litigation tail. CEO Bill Anderson framed it as deleveraging. The shares sold off on the news and implied vol jumped.

Textbook setup, green on the screen

I was set up the way the textbook wants you to be for an event like this: long gamma, long vega, through a long (down-and-in) put on the name. When the stock gapped lower and vol repriced, both of those legs printed. On the greeks I was told to watch — delta convexity and vol — I was green. Clean trade, on paper.

Where the P&L leaked: dividends

Except I still gave a chunk of it back, and the culprit wasn't on the risk screen most people stare at: dividends. A long put is short the forward. Cut the expected dividend and the forward F = S·e^(r−q)T rises — which pushes put values down. My position had positive sensitivity to the dividend yield, and Bayer had just taken a machete to it. So my dividend P&L was negative, and it clipped a real slice off the gamma/vega gains. Net positive on the day, but noticeably less than the "I was long gamma into a crash, of course I won" story would suggest.

Same read, wrong maturity

A colleague had the same directional read and lost money outright. The difference was maturity: his optionality sat in December 2026 paper. Dividend sensitivity scales with time to expiry — a three-year dividend cut strips many more expected payments out of a 2026 option than out of a front-month. His forward moved more, and long-dated options carry far less gamma, so he had little convexity to offset it. He called the move correctly and still ended the day red, because the dividend leg swamped everything else.

The lesson

On a dividend event your directional and vol greeks can be dead right and your P&L still disappoints — because dividend risk is a separate axis(rho-q, the forward), and it's the one that grows with maturity. Before the announcement, know your book's dividend sensitivity, not just its delta, gamma and vega — especially on long-dated or barrier structures where the forward does most of the work. The people who got hurt on Bayer weren't wrong about direction. They were long the wrong maturity of the right idea.

The same forward mechanics drive the down-and-in put in the Barrier pricer, and the delta-hedged gamma P&L behind the story is worked through in the greeks reasoning primer.